<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/31BFCE35-91AA-4E98-B17C-F7DC9D009EB2"><gtr:id>31BFCE35-91AA-4E98-B17C-F7DC9D009EB2</gtr:id><gtr:name>Oxford Centre for Drug Delivery Devices (OxCD3)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/393F6141-9894-4AB4-AB04-3537DE28996A"><gtr:id>393F6141-9894-4AB4-AB04-3537DE28996A</gtr:id><gtr:name>Precision Nanosystems</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Weatherall Inst of Molecular Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/31BFCE35-91AA-4E98-B17C-F7DC9D009EB2"><gtr:id>31BFCE35-91AA-4E98-B17C-F7DC9D009EB2</gtr:id><gtr:name>Oxford Centre for Drug Delivery Devices (OxCD3)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/393F6141-9894-4AB4-AB04-3537DE28996A"><gtr:id>393F6141-9894-4AB4-AB04-3537DE28996A</gtr:id><gtr:name>Precision Nanosystems</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/60C77415-2DC0-4359-920E-6BEAA3C15CAB"><gtr:id>60C77415-2DC0-4359-920E-6BEAA3C15CAB</gtr:id><gtr:firstName>Terence</gtr:firstName><gtr:surname>Rabbitts</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ000612%2F1"><gtr:id>57788B8B-A7D4-46DB-A30D-D8FEA8FF965D</gtr:id><gtr:title>Chromosomal translocation genes and their protein interactions in cancer</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J000612/1</gtr:grantReference><gtr:abstractText>Specific chromosomal translocations are abnormal chromosomes found in most human cancers and are part of the reason why people get cancer. Each cancer has a special type of abnormal chromosome and this change in the structure of the chromosome causes proteins to work incorrectly or even to joining with other proteins to give what is known as fusion or chimaeric proteins. These are invariably proteins inside the cancer cell that function by finding partners and binding to them, often with other partner proteins then joining to make bigger and bigger complexes. We plan to work out how the proteins from chromosomal translocation contribute to cancer by studying what happens when cancers start and which proteins they like to bind to in normal cells and in cancer cells. Many cancers occur in patients because of these abnormal proteins but these are hard to understand and to find drugs that will block them. Some proteins in leukaemias (such as MLL and LMO2) have been extensively studied in both cancer and normal cells and one challenge is to understand how the abnormal expression influences the type of cancer and to determine at which level the protein influences the process of cancer formation. Thus, if a translocation occurs in the cancer forming cell (called a cancer initiating cell), there will be changes in the way the cells works with its RNA and protein milieu being altered. We will try to find out how the two proteins work and investigate the role of a protein called KRAS, that is different from normal in about 25% of all human cancers. RAS can be expressed in one location (e.g. bone marrow) but cancers can arise elsewhere (e.g. brain). We will implement a new fast method to add tracking devices to cancer cells in order that we can see where they start and where they finish in cancer. We will be able to use this new technology to question MLL and LMO2 and RAS proteins. The studies will contribute to mapping cancer origins, to understanding of the puzzling assortment of facets of cancer, why cancer cells move from one place to another in cancer and lead to development of new therapies. The programme will also contribute to understanding of basic problems in blood development, bone marrow development and cancer biology and to the unmet need of finding and confirming cancer drug targets.</gtr:abstractText><gtr:technicalSummary>The programme will be a continuation of my current MRC programme grant and builds on some new observations about chromosomal translocations in cancer development. We will focus on three related areas involving chromosomal translocation genes, viz. the LMO2 translocation gene protein in cancer and in haematopoiesis and synergy with the IL2 receptor gamma common chain in leukaemia; cancer lineage control by chromosomal translocation fusion genes such as MLL-AF4, ENL and AF9 and BCR-ABL; cancer lineage control by mutant signaling molecules resulting in liver neoplasias and a new model of haemangioblastoma. We will refine further our de novo translocation (translocator) technology to incorporate reporter genes for tracking cancer initiating cells and to incorporate co-operating oncogenes to study the role of fusions genes. We will develop new approaches to study and interfere with protein-protein interactions in cancer. The new technologies proposed that will add further levels of complexity to more accurately recapitulate human disease counterparts and the new approaches will be transferable to other labs, for instance resources such as the proposed serially targeted ES cells.

The research objectives are therefore to understand the function chromosomal translocation genes and their protein interactions in cancer and to solve basic problems in haematopoiesis and cancer biology. For exploitation of the research results, we will contribute knowledge for the unmet need of cancer target validation and corroborating protein complexes as targets for therapy. The programme is technology driven including new ways to produce highly specific and rapid models of the effects of chromosomal translocation genes, methods to identify natural components of protein complexes and approaches to confirm that chromosomal translocation genes or mutant proteins are valid drug targets. The latter is an important spin-off as a precursor to expensive and lenghty drug development.</gtr:technicalSummary><gtr:potentialImpactText>The work proposed will have a major impact on understanding how chromosomal translocations control the transition from the cancer initiating cell through to overt, symptomatic cancer and the control of lineage specification when the translocation occurs in a pluripotent or multipotent cell. Further, the work will impact on understanding the molecular events that underlie lineage reassignment when a translocation takes place in a semi-committed cell that retains some plasticity for differentiation. Thus the benefits of the work will mainly and initially be in the academic arena, but including and beyond cancer biology, because we will have described further functions of transcription and signaling in the process of cell fate decision. Further, the validation of chromosomal translocation proteins as cancer targets will eventually be used by the biotechnology and pharmaceutical industry to guide development of diagnostic, prognostic and therapeutic strategies. Time frames for these benefits will vary, with the therapeutic outcome being the longest to achieve. Typically greater than 20 years is needed from academic research findings to be translated to the benefit of public health. It is, however, hoped that directed translational research will accelerate this process and the gathering knowledge of mutant proteins in cancer will facilitate greater focus on the development of public health applications.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2042623</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>MedImmune</gtr:department><gtr:description>Medimmune agreement</gtr:description><gtr:id>2E8E6041-B151-4CFB-865A-23484960906C</gtr:id><gtr:impact>N/a</gtr:impact><gtr:partnerContribution>MedImmune will generate and provide super-charged proteins</gtr:partnerContribution><gtr:piContribution>We will provide in vitro &amp;amp; in vivo lung cancer models with known mutations to test engineered proteins in the ability to enter cells and produce a therapeutic effect.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford Centre for Drug Delivery Devices (OxCD3)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OxCD3</gtr:description><gtr:id>16606A28-117C-4C5E-9E40-4C3887A68EB4</gtr:id><gtr:impact>n/a</gtr:impact><gtr:partnerContribution>The engineers will provide the expertise in localized perturbation in vivo at tumour sites for release of the payload (i.e antibody fragments)</gtr:partnerContribution><gtr:piContribution>The OxCD3 Centre will transform both clinical and industry practice in drug delivery by demonstrating the value and feasibility of engineering approaches, involving a combination of stimulus-responsive nanocarriers and medical devices for improved tumour uptake and therapeutic outcome. we will provide characterised antibody fragments that are known to prevent tumour growth for incorporation into this trial system.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Prof Pamela Kearns, University of Birmingham</gtr:description><gtr:id>A526A2D8-00BB-4DA1-9AF2-585AE30CFE8E</gtr:id><gtr:impact>Contributions made: human T-ALL samples from patients are received following the transplantation into immuno-deficient mice. We have propagated these further in NGS mice and made stocks for investingating drug inhibitors of T-ALL/
Partner Contributions: Prof Kearns is a Clinical Haematologist and works with T-ALL patients. The material provided is karyotyped and transplanted for our work.</gtr:impact><gtr:partnerContribution>Partner Contributions: Prof Kearns is a Clinical Haematologist and works with T-ALL patients. The material provided is karyotyped and transplanted for our work.</gtr:partnerContribution><gtr:piContribution>Contributions made: human T-ALL samples from patients are received following the transplantation into immuno-deficient mice. We have propagated these further in NGS mice and made stocks for investingating drug inhibitors of T-ALL/</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Precision Nanosystems</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Precision Nanosystems</gtr:description><gtr:id>660B1EB2-8050-47E0-B4D3-9DF888702E69</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partnerContribution>Precision provide the lipid nanoparticle components encapsulation and perform this process before sending the nanoparticles to us for cell-based expression assays. When we have established final data &amp;amp; parameters about LNP size and loading, Precision will provide the nanoparticle components to my lab and we will do the encapsulation since the plasmids we intend to use at that stage are not allowed to be transferred for IP reasons.</gtr:partnerContribution><gtr:piContribution>We will provide plasmids that code for expression of fluorescent proteins for encapsulating in lipid nanoparticles to establish methods to insert these vectors as cargo for in vivo use.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Undergraduate students and their lecturers</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5F05FC5B-38CA-4EA5-BAFA-11DFE976B38E</gtr:id><gtr:impact>Talks were given by experts on the technologies being demonstrated, which prompted a number of questions from staff and students about the instruments and the work of the scientists at the Institute.

Received a formal thank you letter from the group thanking us for an 'inspirational' day. The group have written a post for the WIMM blog describing their experiences.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>A4E08ACB-51A6-41E3-806C-E8C72137167C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2345550</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Senior Investigator Award</gtr:department><gtr:description>Wellcome Trust SI Award</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>B2BE84D5-6E6C-4663-8FDE-6733231CB0E3</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>376000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust/EPSRC</gtr:fundingOrg><gtr:id>65C3D4A3-B45A-4F41-88EA-84E9097E7B80</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3825714</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Seeding Drug Development Award</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>25471C3D-7C33-43F8-8779-353E28504893</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>New sarcoma cell surface targets have been identified and include LINGO-1, KCNN1 and CDH23. Specific binding agents that specifically bind to these targets include antibodies and aptamers. Methods of treating sarcoma utilize the specific binding agents. Methods of diagnosing and detecting sarcoma, including metastases and residual disease involve determining the expression of LINGO-1, KCNN1 and CDH23.</gtr:description><gtr:id>0E297207-1FD0-420F-A93B-960368C34AAB</gtr:id><gtr:impact>z</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2015/121688</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>BIOMARKERS AND THERAPEUTIC TARGETS FOR SARCOMA</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An in vitro drug discovery platform analogous to phage display but with considerable advantages</gtr:description><gtr:id>9D705C9D-650E-40DF-99B0-FF7CCD7DE6CB</gtr:id><gtr:impact>z</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO 2015/011467</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>IDENTIFICATION AND DISPLAY OF PEPTIDE LIGANDS</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to sarcoma. Provided are molecules and methods for detecting and treating sarcoma in a subject. Kits and systems useful in the methods are also described.</gtr:description><gtr:id>D9B1038A-1D44-4335-BB0D-1D420D343D63</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Patent application published</gtr:protection><gtr:title>Biomarker and Therapeutic Target for Sarcoma</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to methods of designing binding partners capable of interacting with protein-protein interaction-forming portion of a target protein. The binding partners may be inhibitors of protein-protein interactions. The invention also relates to novel peptides and their derivatives, as well as to the uses of such peptides and derivatives, pharmaceutical compositions compromising such novel peptides and derivatives, and methods of treatment employing such novel peptides and derivatives.</gtr:description><gtr:id>6F16421F-80F2-4909-8173-41A3290D714A</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Patent application published</gtr:protection><gtr:title>Binding Partners and Inhibitors</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An in vitro drug discovery platform analogous to phage display but with considerable advantages</gtr:description><gtr:id>1277AB19-C072-42DA-B14B-3FA318731E16</gtr:id><gtr:impact>z</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>EP3024932(A1)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>IDENTIFICATION AND DISPLAY OF PEPTIDE LIGANDS</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>New sarcoma cell surface targets have been identified and include LINGO-1, KCNN1 and CDH23. Specific binding agents that specifically bind to these targets include antibodies and aptamers. Methods of treating sarcoma utilize the specific binding agents. Methods of diagnosing and detecting sarcoma, including metastases and residual disease involve determining the expression of LINGO-1, KCNN1 and CDH23.</gtr:description><gtr:id>6C040AE0-133D-48DE-9A0A-4EEC715DBA5D</gtr:id><gtr:impact>z</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>EP3107936(A1)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>BIOMARKERS AND THERAPEUTIC TARGETS FOR SARCOMA</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This invention relates to the identification of peptide ligands and the DNA encoding the peptide ligands. The invention also relates to carriers for use in the identification of peptide ligands.</gtr:description><gtr:id>7402D4DD-9632-478F-B64E-236965E9381F</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Patent application published</gtr:protection><gtr:title>Identification of Peptide Ligands</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An in vitro drug discovery platform analogous to phage display but with considerable advantages</gtr:description><gtr:id>FD9952B4-C9D8-485A-981D-B2020957B7AD</gtr:id><gtr:impact>z</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US20160298109(A1)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>IDENTIFICATION AND DISPLAY OF PEPTIDE LIGANDS</gtr:title><gtr:yearProtectionGranted>2017</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>New sarcoma cell surface targets have been identified and include LINGO-1, KCNN1 and CDH23. Specific binding agents that specifically bind to these targets include antibodies and aptamers. Methods of treating sarcoma utilize the specific binding agents. Methods of diagnosing and detecting sarcoma, including metastases and residual disease involve determining the expression of LINGO-1, KCNN1 and CDH23.</gtr:description><gtr:id>9020C325-3DA5-4B9B-BEA6-A8DB2345C95D</gtr:id><gtr:impact>z</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2017010266 (A1)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>BIOMARKERS AND THERAPEUTIC TARGETS FOR SARCOMA</gtr:title><gtr:yearProtectionGranted>2017</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3A878C43-848B-4FB8-94DE-8C39031AE9BB"><gtr:id>3A878C43-848B-4FB8-94DE-8C39031AE9BB</gtr:id><gtr:title>Peptides: minimal drug surrogates to interrogate and interfere with protein function</gtr:title><gtr:parentPublicationTitle>MedChemComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a71386f57d59fc2da3bf8ea907a90629"><gtr:id>a71386f57d59fc2da3bf8ea907a90629</gtr:id><gtr:otherNames>Cruz-Migoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52342913-960D-47EA-9B42-5E21BA59E5B0"><gtr:id>52342913-960D-47EA-9B42-5E21BA59E5B0</gtr:id><gtr:title>Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c6db4980da9950901817c6329d35d045"><gtr:id>c6db4980da9950901817c6329d35d045</gtr:id><gtr:otherNames>McCormack MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4AECD104-0FB7-4C80-B4EE-9EC3FAA058A2"><gtr:id>4AECD104-0FB7-4C80-B4EE-9EC3FAA058A2</gtr:id><gtr:title>Sequential gene targeting to make chimeric tumor models with de novo chromosomal abnormalities.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c76bd2fef256dbb400ce04c1486770e8"><gtr:id>c76bd2fef256dbb400ce04c1486770e8</gtr:id><gtr:otherNames>Chambers JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/744DCFDB-B806-4748-97EC-2635C500D98B"><gtr:id>744DCFDB-B806-4748-97EC-2635C500D98B</gtr:id><gtr:title>Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e4005dccb25e6d372cda6ab7db0fe727"><gtr:id>e4005dccb25e6d372cda6ab7db0fe727</gtr:id><gtr:otherNames>Town J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1DB9A99C-3F63-4C4A-B41F-AF8A2DFEBC92"><gtr:id>1DB9A99C-3F63-4C4A-B41F-AF8A2DFEBC92</gtr:id><gtr:title>Intracellular antibody capture: A molecular biology approach to inhibitors of protein-protein interactions.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f5ff2310b21823fdc45326aba6a7d2d"><gtr:id>6f5ff2310b21823fdc45326aba6a7d2d</gtr:id><gtr:otherNames>Zhang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E78C6492-6550-4FE3-811E-000FF9C4767B"><gtr:id>E78C6492-6550-4FE3-811E-000FF9C4767B</gtr:id><gtr:title>Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea3e49ac70cf3f24e795eefd5d09fadc"><gtr:id>ea3e49ac70cf3f24e795eefd5d09fadc</gtr:id><gtr:otherNames>Sewell H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9403C1E1-E4FD-474C-B265-4D80427589B6"><gtr:id>9403C1E1-E4FD-474C-B265-4D80427589B6</gtr:id><gtr:title>Selection of functional single domain antibody fragments for interfering with protein-protein interactions inside cells: a &amp;quot;one plasmid&amp;quot; mammalian two-hybrid system.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B4C999B4-A4F3-46DD-997B-E126B8A539C3"><gtr:id>B4C999B4-A4F3-46DD-997B-E126B8A539C3</gtr:id><gtr:title>Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93e0024b1d7ccf0ae91dcd4ac4bce74d"><gtr:id>93e0024b1d7ccf0ae91dcd4ac4bce74d</gtr:id><gtr:otherNames>Li BE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F6C858C6-1CDC-432C-A79B-781CDD3F02B8"><gtr:id>F6C858C6-1CDC-432C-A79B-781CDD3F02B8</gtr:id><gtr:title>Single Domain Antibody Fragments as Drug Surrogates Targeting Protein-Protein Interactions inside Cells</gtr:title><gtr:parentPublicationTitle>Antibodies</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c5dd22e69937cc91b3f56ac7eae76ea"><gtr:id>9c5dd22e69937cc91b3f56ac7eae76ea</gtr:id><gtr:otherNames>Zeng J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98C20A38-040E-40FC-A6A7-C8126E4DFF66"><gtr:id>98C20A38-040E-40FC-A6A7-C8126E4DFF66</gtr:id><gtr:title>LMO2 at 25 years: a paradigm of chromosomal translocation proteins.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/590bf6865bfab157d61e6d2761727937"><gtr:id>590bf6865bfab157d61e6d2761727937</gtr:id><gtr:otherNames>Chambers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD1E93D8-993F-487F-B83D-D09C8886D2C6"><gtr:id>FD1E93D8-993F-487F-B83D-D09C8886D2C6</gtr:id><gtr:title>Nonreciprocal chromosomal translocations in renal cancer involve multiple DSBs and NHEJ associated with breakpoint inversion but not necessarily with transcription.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ec7718605084ef32a3392fb3199ce1a0"><gtr:id>ec7718605084ef32a3392fb3199ce1a0</gtr:id><gtr:otherNames>Ali H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DE778AAF-4085-4F06-AC04-C6AA64414F9C"><gtr:id>DE778AAF-4085-4F06-AC04-C6AA64414F9C</gtr:id><gtr:title>Intracellular antibody capture (IAC) methods for single domain antibodies.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2563E61-A2D9-439C-A150-FAA82DB6C41D"><gtr:id>C2563E61-A2D9-439C-A150-FAA82DB6C41D</gtr:id><gtr:title>Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/979618619d408adb8062781f20fb5699"><gtr:id>979618619d408adb8062781f20fb5699</gtr:id><gtr:otherNames>El-Jawhari JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J000612/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>